SGLT-2 inhibitors have been approved for T2DM in many countries, and their efficacy and safety have been widely recognized.[7] However, the efficacy and safety of SOTA adjuvant therapy for T1DM remain controversial. Here, SLC5A2 is linked to type 2 diabetes mellitus.